Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/262415
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change? |
Autor: | Jiménez-Ubieto, Ana; Paiva, Bruno; Puig, Noemi; Cedena, Maria-Teresa; Martínez-López, Joaquín; Oriol, Albert; Blanchard, María Jesús; Ríos, Rafael; Martín, Jesús; Martínez, Rafael; Sureda, Anna; Hernandez, Miguel T.; Rubia, Javier de la; Krsnik, Isabel; Cabañas, Valentin; Palomera, Luis; Sánchez-Pina, José María; Bargay, Joan; Mateos, Maria Victoria; Rosiñol, Laura; Bladé, Joan; San Miguel, Jesús F. CSIC ORCID; Lahuerta, Juan José | Palabras clave: | Clinical Trials and Observations Lymphoid Neoplasia Transplantation |
Fecha de publicación: | 11-nov-2021 | Editor: | American Society of Hematology | Citación: | Blood 138(19): 1901-1905 (2021) | Resumen: | Induction and consolidation based on proteasome inhibitors, immunomodulatory drugs, and corticoids integrated with high-dose therapy (HDT) and autologous stem cell transplantation (ASCT), are showing complete response (CR) rates >50% in multiple myeloma (MM).1-3 The addition of anti-CD38 monoclonal antibodies may increase these unprecedented CR rates.4-6 When more than half of transplant-eligible patients with MM achieve CR with frontline therapy, it is reasonable to ask, what other tests are clinically relevant after negative immunofixation. The achievement of deep responses with modern therapy led the International Myeloma Working Group (IMWG) to propose new guidelines that included definitions of negative minimal residual disease (MRD) for standard response criteria.7 Indeed, recent studies have reported nearly 50% MRD− rates,5,8,9 and, more importantly, the prognostic value of MRD criteria was validated in clinical trials8,10-12 and routine practice.... | Versión del editor: | http://dx.doi.org/10.1182/blood.2021012319 | URI: | http://hdl.handle.net/10261/262415 | DOI: | 10.1182/blood.2021012319 | ISSN: | 0006-4971 | E-ISSN: | 1528-0020 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
20
checked on 21-abr-2024
WEB OF SCIENCETM
Citations
16
checked on 22-feb-2024
Page view(s)
59
checked on 23-abr-2024
Download(s)
7
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.